Eton Pharmaceutcials Inc ETON

$51.80 +0.64 (1.25%)

Valuation

Market cap
1,586,357,000
Revenue TTM
$79,950,000
Net income TTM
$-4,600,000
PE ratio
150.18
Forward PE
44.44
Profit margin
-5.75%
Debt to equity
0.60

Trading

Volume
339,600
Avg volume
534,526
Day's range
$50.51 – $51.97
Shares out
28,583,000
Stochastic %K
95%
Beta
0.90
Analysts
Strong Sell
Price target
$64.50

Price

Company profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn...

Show more

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
847 787 7361
Website
https://www.etonpharma.com
Address
21925 W. Field Parkway, Suite 235, Deer Park, United States

Latest news

Stocktwits

investpapaya Oct 22, 11:14 AM
$ETON What is the support for this stock going to be? 40? 50? Discuss.
1 replies
Dbarnyard Oct 21, 3:48 PM
$ETON Opaleye dumping more? Wait till they really start dumping...
0 replies
shawn45 Oct 19, 7:34 PM
$AQST Just only Libervant Blockbuster Seizure Drug, AQST is targeting in US only about 450,000,000 +Million Dollar Annual Sales. LOL this is going to be a huge. CANADA, UK also coming in for Libervant. Its going ro explode in Sales. $ETON Eton is not a small company, it's Multi Billion dollar Marke cap company. AQST with ETON libervant partnerships going ro be huge soon. NOW with Sidley represents. MEGA EXPLOSION coming in for AQSTnand ETON for Libervant December and January US FDA full approval and January 9th Libervant full Market exclusitivity rights with AQST worldwide. This AQST stock could explode anytime.. $TSLA $NVDA $MU Now add the Annaphylm in March. EXPLOSION..
0 replies
shawn45 Oct 19, 7:29 PM
$AQST $ETON https://www.sidley.com/en/newslanding/newsannouncements/2026/10/sidley-represents-aquestive-therapeutics-in-exclusive-us-licensing-agreement
0 replies
Dusan8989 Oct 15, 7:49 PM
$ETON where do you see it in 2027?
2 replies
prismmarketview Oct 14, 1:09 PM
$AQST has licensed exclusive U.S. rights to LIBERVANT®, its seizure-rescue film, to $ETON . Aquestive stays on as manufacturer and could earn milestones and royalties. Eton expects to launch in April 2027. 👇 https://prismmarketview.com/aquestive-hands-u-s-rights-to-libervant-to-eton-as-it-prepares-for-an-april-2027-launch/
0 replies
LibertarianTreehugger Oct 14, 1:07 PM
Eton Pharmaceuticals and Aquestive Therapeutics Team Up to Bring New Epilepsy Treatment to Patients: https://jlsfund.substack.com/p/eton-pharmaceuticals-and-aquestive $ETON $AQST
0 replies
filecrux Oct 14, 11:32 AM
$ETON Follow-up: Rare-disease drugmaker Eton Pharmaceuticals paid Aquestive $10.0M upfront for U.S. rights to LIBERVANT seizure-rescue film, announced Oct 14, and owes up to $47.5M in milestones plus a mid-teens royalty on net sales. That upfront is ~37% of the $26.8M cash held June 30, though H1 2026 operating cash flow was $14.7M. Aquestive is sole supplier for 20 years. Launch is eyed April 2027, subject to final FDA approval: LIBERVANT is tentatively approved, expected to qualify for full ages 12+ approval as VALTOCO's exclusivity ends Jan 10, 2027.
0 replies